Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 73 of 5804
-
New hope for Hard-to-Treat breast cancer: Head-to-Head drug trial launches
Disease control OngoingThis is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (H…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
AI-Powered blood test could spot colon cancer before it spreads
Diagnosis Recruiting nowThis is a prospective, multicenter, case-control study. The aim is to develop an optimized algorithm by combining the levels of molecular markers in plasma together with risk factors for developing colorectal cancer and clinical data of patients diagnosed with CRC or AA and healt…
Sponsor: ADVANCED MARKER DISCOVERY S.L. • Aim: Diagnosis
Last updated Jun 27, 2026 07:52 UTC
-
Ecstasy-Assisted therapy shows promise for veterans haunted by war
Disease control Recruiting nowThe overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of methylenedioxymethamphetaminel, in participants with Post traumatic Stress Disorder and moral i…
Phase: PHASE2 • Sponsor: HaEmek Medical Center, Israel • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Radioactive 'Smart Bomb' targets melanoma in first human test
Disease control Recruiting nowIn this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with nivolumab in subjects with unresectab…
Phase: PHASE1, PHASE2 • Sponsor: Perspective Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Gene therapy breakthrough? new trial targets duchenne muscular dystrophy
Disease control OngoingThe study will evaluate the safety and efficacy of delandistrogene moxeparvovec gene transfer therapy in non-ambulatory and ambulatory males with DMD. This is a randomized, double-blind, placebo-controlled 2-part study. Participants will be in the study for approximately 128 week…
Phase: PHASE3 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for tough lung cancer: tarlatamab takes on relapsed SCLC
Disease control OngoingThe main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Heated chemo during surgery could extend lives in ovarian cancer
Disease control Recruiting nowPrimary stage III-IV epithelial ovarian cancer randomizing between interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC)
Phase: PHASE3 • Sponsor: National Cancer Center, Korea • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New weekly shot could help severely obese heart patients shed pounds
Disease control OngoingThe main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug duo shows promise against aggressive colon cancer
Disease control OngoingEvaluate efficacy and safety of IBI310 (CTLA-4 antibody) in combination with Sintilimab, for neoadjuvant treatment of MSI-H/dMMR resectable colon cancer
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Magic mushroom therapy aims to ease cancer Patients' fear of death
Symptom relief Recruiting nowThe purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existential distress (i.e., loss of meaning and hope; fear of death) in advanced cancer …
Phase: PHASE2, PHASE3 • Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
New targeted therapy aims to beat back childhood leukemia relapse
Disease control Recruiting nowThis prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle of induction treatment in paediatric participants (between 1 and \<18 years) with High Risk (HR) or very high risk (VHR) first bon…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could stem cell islets end daily insulin shots?
Disease control OngoingThe purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Phase: PHASE1, PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo therapy aims to boost survival in hodgkin lymphoma
Disease control Recruiting nowThis phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Br…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Double attack: new CAR t therapy targets two cancer proteins in aggressive lymphoma
Disease control Recruiting nowThis is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggress…
Phase: PHASE1, PHASE2 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Stroke treatment showdown: is removing the clot alone enough?
Disease control Recruiting nowTo assess the effect of endovascular thrombectomy alone compared to intravenous thrombolysis plus endovascular thrombectomy in acute basilar artery occlusion patients within 4.5 hours from onset on efficacy and safety outcomes.
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of University of Science and Technology of China • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug shows promise in slowing advanced breast cancer
Disease control OngoingThe goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to currently available standard treatments, such as paclitaxel, nab-paclitax…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Could a vaccine stop colon cancer in lynch syndrome patients?
Prevention OngoingThis phase IIb trial tests whether Tri-Ad5 in combination with N-803 works to prevent colon and other cancers in participants with Lynch syndrome. Each of the three injections in Tri-Ad5 vaccine contain a different substance that is in precancer and cancer cells. Injecting these …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells injected directly into the brain take on childhood tumors
Disease control OngoingThis is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with SC-CAR4BRAIN, an autologous CD4+ and CD8+ T cells lentivirally transduced to express to express combinations of B7-H3, EGFR806, HER2, and IL13-zetakine chimeric antigen receptors (CAR). CAR…
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Meningitis b vaccine tested as gonorrhea shield in men
Prevention OngoingObjectives: Efficacy of a meningococcal vaccine against Neisseria gonorrhoea (NG) infection among men who have sex with men (MSM). Design: Parallel randomised double-blind placebo-controlled trial. Setting: A teaching hospital in Hong Kong. Participants: 150 adult MSM at risk …
Phase: PHASE3 • Sponsor: Chinese University of Hong Kong • Aim: Prevention
Last updated Jun 27, 2026 11:03 UTC
-
AI could spot psychosis risk before it strikes
Prevention CompletedMulticenter randomized controlled trial (RCT) with artificial intelligence (AI)-staged early diagnostics and risk-adapted treatment (RAB) as interventional treatment arm and treatment-as-usual (TAU) as control treatment arm for patients with an increased clinical risk for psychos…
Phase: NA • Sponsor: Heinrich-Heine University, Duesseldorf • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC